Aptevo Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology company developing immune-oncology candidates based on ADAPTIR and ADAPTIR-FLEX platforms. Its 8-K reports record clinical updates for mipletamig in acute myeloid leukemia, annual financial results, material agreements, executive and board changes, and other public-company events.
The company’s proxy and registration filings disclose shareholder voting matters, proposed charter and administrative amendments, Nasdaq share-issuance approvals, common-stock financing arrangements, and capital-structure information related to its standby equity purchase agreement. These filings also provide formal context for governance, securities issuance mechanics, and the funding disclosures associated with Aptevo’s oncology pipeline.
Aptevo Therapeutics Inc. (APVO) reported new early clinical data for its lead candidate mipletamig in frontline acute myeloid leukemia (AML) patients with TP53 mutations, a historically hard-to-treat subgroup. In 14 evaluable patients treated with mipletamig plus venetoclax and azacitidine, 13 patients (93%) showed clinical benefit, and 11 patients (79%) achieved complete remission or complete remission with incomplete hematologic recovery, including 9 complete remissions. The composite remission rate compares with a published 41% remission rate for venetoclax plus azacitidine alone in a similar high‑risk population. The ongoing RAINIER Phase 1b/2 trial is in the dose-optimization phase, which is expected to complete by year-end, with regulatory interaction planned in the first half of 2027 to determine next steps. Mipletamig has orphan drug designation in AML, and Aptevo continues to advance a broader pipeline of bispecific and trispecific immunotherapies and radiopharmaceutical programs.
Aptevo Therapeutics Inc. (APVO) is calling a virtual special stockholder meeting on September 22, 2026 to vote on four proposals. Proposal 1 would adopt an amended and restated certificate of incorporation that consolidates prior amendments, updates the company’s address, confirms perpetual duration, incorporates the Series A Junior Participating Preferred Stock designation, and makes technical and administrative clarifications.
Proposal 2 seeks stockholder approval under Nasdaq Listing Rule 5635(d) for the potential issuance of 20% or more of existing common shares or voting power through Inducement Warrants and Common Warrants. These include 1,274,610 Inducement Warrants, 861,708 Pre-Funded Warrants, and 4,308,540 Common Warrants, each with a $4.03 exercise or purchase price. The related August 2026 transactions generated approximately $4.5 million in gross proceeds, with up to about $1.0 million of additional proceeds from exercised prior warrants. Without approval, the Inducement and Common Warrants are not exercisable and the company must keep calling meetings every 60 days while the warrants remain outstanding.
Proposal 3 would approve the Fifth Amended and Restated 2018 Stock Incentive Plan, adding 180,000 new shares (plus up to 152,360 remaining under the current plan and certain returning shares), with a new plan term through 2036 and governance features such as no repricing, minimum one-year vesting (with limited exceptions), director award caps, no tax gross-ups, and clawback provisions. Proposal 4 would allow adjournment of the meeting to solicit more proxies if needed. The board recommends voting “FOR” all four proposals.
Aptevo Therapeutics Inc. (APVO), a Delaware biotechnology company, filed a Form D for a private exempt offering under Regulation D Rule 506(c). The offering consists of equity securities and warrants or other rights to acquire securities.
The notice reports that Aptevo has sold $3,472,683 USD in this offering, with $0 remaining to be sold, and the date of first sale was August 12, 2026$0 in finders’ fees and discloses an additional $90,000 in placement agent expenses.
Aptevo Therapeutics Inc. (APVO) is calling a virtual special stockholder meeting on September 22, 2026 to vote on four proposals. Stockholders of record on August 13, 2026, when 1,801,970 common shares were outstanding, are entitled to vote.
Proposal 1 seeks approval of an amended and restated certificate of incorporation that consolidates prior amendments, updates the company address, confirms perpetual duration, incorporates the Series A Junior Participating Preferred Stock designation, and makes other technical changes.
Proposal 2 asks stockholders, under Nasdaq Listing Rule 5635(d), to approve the potential issuance of 20% or more of current voting power through common stock and warrant exercises, including Inducement Warrants and Common Warrants issued in August 2026. The related private placements generated approximately $4.5 million in gross proceeds and could add substantial new shares if exercised.
Proposal 3 would approve the Fifth Amended and Restated 2018 Stock Incentive Plan, adding 180,000 new shares (market value $496,800 at $2.76 on August 20, 2026) to the existing reserve, with total equity plan overhang projected at 4.17% after the increase. Proposal 4 would permit adjournment of the meeting to solicit additional proxies if needed. The board recommends voting “FOR” all four proposals.
Aptevo Therapeutics Inc. (APVO) filed a Form S-1 to register for resale up to 6,444,858 shares of Common Stock issuable upon exercise of outstanding pre-funded warrants, common warrants and inducement warrants held by selling stockholders. These are secondary sales; Aptevo states it will not receive any proceeds from the resale of these shares.
The registered shares comprise up to 861,708 Pre-Funded Warrant Shares, 4,308,540 Common Warrant Shares and 1,274,610 Inducement Warrant Shares. Common stock outstanding was 1,810,215 shares as of August 21, 2026, and this figure is unchanged immediately after the offering, excluding the Resale Shares. APVO trades on Nasdaq Capital Market, where the stock last closed at $2.76 per share on August 20, 2026.
Aptevo is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary ADAPTIR and ADAPTIR-FLEX platforms, with two clinical candidates (mipletamig for AML and ALG.APV-527 for solid tumors) and multiple preclinical bispecific and multi-specific antibody programs. The company highlights prior equity financings, a collaboration with Niowave in radioligand oncology, and notes continued eligibility as a smaller reporting company.
Aptevo Therapeutics Inc. (APVO) reported the results of its 2026 Annual Meeting of Stockholders held on August 21, 2026. A quorum was present and four proposals were voted on.
Stockholders elected two directors, Zsolt Harsanyi, Ph.D. and Barbara Lopez Kunz, to the board to serve until the 2029 Annual Meeting and until their successors are elected and qualified. Baker Tilly US, LLP was approved as independent registered public accounting firm for the year ending December 31, 2026. Stockholders approved, on an advisory basis, the compensation of the company’s named executive officers for 2025, and also approved Aptevo’s Fourth Amended and Restated 2018 Stock Incentive Plan.
CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of Aptevo Therapeutics Inc. common stock through warrants. They report beneficial ownership of 83,854 Shares, representing 6.3% of Aptevo’s common stock based on 1,246,105 Shares outstanding as indicated in the company’s Form 10-Q filed on May 13, 2026.
The reported position consists entirely of Shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership limitation. Heights Capital Management acts as investment manager to CVI Investments and may be deemed to share voting and dispositive power, while both parties disclaim beneficial ownership beyond their pecuniary interest.
Aptevo Therapeutics Inc., a clinical-stage oncology biotech, reported a net loss of $13.1 million for the six months ended June 30, 2026 and an accumulated deficit of $288.3 million. Cash and cash equivalents were $9.8 million, with net cash used in operating activities of $13.4 million over the same period, driving a decline in stockholders’ equity to $6.0 million from $17.4 million at year-end 2025.
The company states that recurring losses, negative operating cash flows, and limited cash resources raise substantial doubt about its ability to continue as a going concern for one year from issuance of the financial statements. Management discloses that existing cash is not expected to fund operations for at least that period and that additional capital will be required to advance its pipeline.
Aptevo continues development of lead candidate mipletamig in frontline AML and ALG.APV-527 in solid tumors, alongside multiple preclinical ADAPTIR and ADAPTIR-FLEX assets. Recent non-dilutive and strategic funding steps include a $1.5 million CARE Fund grant commitment for APVO451 and a 50/50 radiopharmaceutical collaboration with Niowave, accompanied by a $0.5 million equity investment. Equity financings in 2025–2026, including Standby Equity Purchase Agreements and warrant transactions, have provided cash but also created a large warrant overhang and, under August 2026 agreements, restrict further use of the SEPAs and ATM facility for 12 months after shareholder approval.
Aptevo Therapeutics Inc. reported that it released its financial results for the period ended June 30, 2026 through a press release dated August 14, 2026. The company furnished this press release as Exhibit 99.1 to a current report on Form 8-K under the results of operations and financial condition disclosure item. The company specifies that this information is being furnished, not filed, which limits its treatment under certain liability provisions and incorporation-by-reference rules in other SEC reports.